Tuberous Sclerosis Drug Pipeline Analysis: Market Trends, Players, and Future Outlook (2034)
According to Expert Market Research, the drug development pipeline for tuberous sclerosis is witnessing significant momentum, driven by unmet clinical needs and advances in targeted therapy. Tuberous sclerosis complex (TSC), a rare genetic disorder caused by mutations in the TSC1 or TSC2 genes, affects an estimated 1 in 6,000 to 10,000 live births. It leads to the growth of benign tumors in...
0 Comments 0 Shares 941 Views 0 Reviews